Security
Cerecor Inc. Class B Warrants · CERCZ
CERCZNASDAQWarrantHistorical · closed Apr 18, 2017CIK 1534120Updated Nov 14, 2026
CERCZ price & chart
This listing closed Apr 18, 2017. Live provider charts are shown only for current listings.
Current security: AVTX
In the news
No coverage from other publishers is available.
Recent filings
SCHEDULE 13G - filed by FARALLON CAPITAL MANAGEMENT, L.L.C. regarding Avalo Therapeutics, Inc.
SCHEDULE 13G - filed by STATE STREET CORP regarding Avalo Therapeutics, Inc.
SCHEDULE 13G/A - filed by FMR LLC regarding Avalo Therapeutics, Inc.
SCHEDULE 13G/A - filed by FMR LLC regarding Avalo Therapeutics, Inc.
Entry into a Material Definitive Agreement · Termination of a Material Definitive Agreement
Items 1.01, 1.02, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 125,100,000Source | 98,455,000Source | 490,783,000Source | 126,583,000Source | 108,307,000Source | 99,885,000Source | 138,523,000Source | 123,728,000Source | 116,458,000Source | 150,732,000Source | 20,993,000Source | 33,367,000Source |
| GoodwillUSD | 10,502,000Source | 10,502,000Source | 10,502,000Source | 10,502,000Source | 10,502,000Source | 10,502,000Source | 10,502,000Source | 10,502,000Source | 10,502,000Source | 10,502,000Source | 10,502,000Source | 14,409,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 26,963,000Source | 81,858,000Source | 85,382,000Source | 42,290,000Source | 93,426,000Source | 24,988,000Source | 125,046,000Source | 110,177,000Source | 15,858,000Source | 134,546,000Source | 7,415,000Source | 13,172,000Source |
| Accounts ReceivableUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Inventory, NetUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 20,000Source |
| Assets, CurrentUSD | 113,846,000Source | 86,148,000Source | 407,932,000Source | 115,185,000Source | 95,894,000Source | 88,825,000Source | 126,941,000Source | 111,213,000Source | 105,286,000Source | 138,890,000Source | 8,395,000Source | 16,416,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,139,000Source | 3,251,000Source | 7,607,000Source | 1,903,000Source | 2,435,000Source | 6,685,000Source | 1,833,000Source | 997,000Source | 6,913,000Source | 3,714,000Source | 843,000Source | 1,290,000Source |
| Operating Lease, Right-of-Use AssetUSD | 402,000Source | 1,139,000Source | 198,000Source | 487,000Source | 1,211,000Source | 268,000Source | 615,000Source | 1,280,000Source | 336,000Source | 741,000Source | 1,329,000Source | 1,750,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 33,553,000Source | 75,721,000Source | 42,123,000Source | 22,009,000Source | 110,458,000Source | 31,565,000Source | 15,908,000Source | 224,813,000Source | 33,409,000Source | 17,700,000Source | 13,689,000Source | 44,282,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 18,000Source | 10,000Source | 53,000Source | 11,000Source | 1,000Source | 25,000Source | 11,000Source | 1,000Source | 18,000Source | 10,000Source | 1,000Source | 9,000Source |
| Additional Paid in CapitalUSD | 526,290,000Source | 355,990,000Source | 953,700,000Source | 508,774,000Source | 344,352,000Source | 536,453,000Source | 506,016,000Source | 343,881,000Source | 531,485,000Source | 503,285,000Source | 342,437,000Source | 292,900,000Source |
| Retained Earnings (Accumulated Deficit)USD | -434,802,000Source | -334,924,000Source | -504,510,000Source | -404,177,000Source | -357,961,000Source | -468,152,000Source | -383,412,000Source | -456,424,000Source | -448,522,000Source | -370,263,000Source | -335,134,000Source | -303,824,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 41,000Source | — | -583,000Source | -34,000Source | — | -6,000Source | — | — | 68,000Source | — | — | — |
| Stockholders' Equity Attributable to ParentUSD | 91,547,000Source | 21,076,000Source | 448,660,000Source | 104,574,000Source | -13,608,000Source | 68,320,000Source | 122,615,000Source | -112,542,000Source | 83,049,000Source | 133,032,000Source | 7,304,000Source | -10,915,000Source |
| Liabilities and EquityUSD | 125,100,000Source | 98,455,000Source | 490,783,000Source | 126,583,000Source | 108,307,000Source | 99,885,000Source | 138,523,000Source | 123,728,000Source | 116,458,000Source | 150,732,000Source | 20,993,000Source | 33,367,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 7,972,000Source | 60,674,000Source | 21,130,000Source | 9,259,000Source | 96,397,000Source | 11,599,000Source | 5,615,000Source | 215,700,000Source | 12,940,000Source | 6,960,000Source | 4,618,000Source | 22,114,000Source |
| Operating Lease, Liability, CurrentUSD | 438,000Source | 550,000Source | 242,000Source | 482,000Source | 548,000Source | 328,000Source | 526,000Source | 545,000Source | 392,000Source | 568,000Source | 537,000Source | 532,000Source |
| Accounts Payable, CurrentUSD | 474,000Source | 1,811,000Source | 3,347,000Source | 2,366,000Source | 654,000Source | 356,000Source | 681,000Source | 916,000Source | 137,000Source | 283,000Source | 446,000Source | 2,882,000Source |
| Operating Lease, Liability, NoncurrentUSD | 117,000Source | 1,083,000Source | 0Source | 197,000Source | 1,183,000Source | 0Source | 275,000Source | 1,281,000Source | 35,000Source | 350,000Source | 1,366,000Source | 1,711,000Source |
| Deferred Income Tax Liabilities, NetUSD | 304,000Source | 154,000Source | 463,000Source | 293,000Source | 168,000Source | 446,000Source | 278,000Source | 162,000Source | 434,000Source | 270,000Source | 155,000Source | 141,000Source |
| Other Liabilities, NoncurrentUSD | 117,000Source | 1,083,000Source | 0Source | 197,000Source | 1,183,000Source | 0Source | 275,000Source | 1,281,000Source | 35,000Source | 350,000Source | 1,366,000Source | 1,711,000Source |
| Additional Financial Items | ||||||||||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 111,600,000Source | — | 472,200,000Source | 113,300,000Source | — | 82,000,000Source | — | — | 98,300,000Source | — | — | — |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 434,000Source | 270,000Source | 155,000Source | 141,000Source |
| Short-term InvestmentsUSD | 84,654,000Source | — | 314,894,000Source | 70,972,000Source | — | 57,005,000Source | — | — | 82,478,000Source | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 17,000Source | 135,000Source | 344,000Source | 169,000Source | 158,000Source | 166,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 3,575,000Source | 3,241,000Source | 13,621,000Source | 5,852,000Source | 3,477,000Source | 7,554,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | — | — | — | — | 0Source | -1,060,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | — | — | — | 0Source | -20,000Source | -18,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 219,000Source | 398,000Source | -146,000Source | -163,000Source | -2,436,000Source | -487,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | 12,000Source | 8,000Source | 165,000Source | 114,000Source | 14,000Source | 28,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -17,691,000Source | -9,457,000Source | -51,458,000Source | -49,056,000Source | -30,680,000Source | -26,751,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 25,505,000Source | 0Source | -81,720,000Source | 356,000Source | -133,000Source | -95,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | — | — | — | 95,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | 779,000Source | 0Source | 510,000Source | — | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 1,399,000Source | 0Source | 14,587,000Source | 175,849,000Source | 25,042,000Source | -14,699,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 9,213,000Source | -9,457,000Source | -118,591,000Source | 127,149,000Source | -5,771,000Source | -41,545,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 27,263,000Source | 82,030,000Source | 85,614,000Source | 42,520,000Source | 25,318,000Source | 125,239,000Source | 16,105,000Source | 134,696,000Source | 7,547,000Source | 13,318,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | — | 0Source | 1,925,000Source | 2,931,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 3,153,000Source | 1,848,000Source | 5,306,000Source | 2,718,000Source | 3,575,000Source | 3,241,000Source | 13,621,000Source | 5,852,000Source | 3,475,000Source | 7,554,000Source |
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 38,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 111,600,000Source | — | 472,200,000Source | 113,300,000Source | 82,000,000Source | — | 98,300,000Source | — | — | — |
| DepreciationUSD | — | — | — | — | — | — | — | — | 300,000Source | 200,000Source | 200,000Source | 100,000Source |
| Gain (Loss) on Termination of LeaseUSD | — | — | — | — | — | — | — | — | 0Source | 309,000Source | — | — |
| General and Administrative ExpenseUSD | — | — | 5,577,000Source | 4,286,000Source | 8,099,000Source | 5,242,000Source | 6,854,000Source | 5,546,000Source | 22,900,000Source | 17,241,000Source | — | 20,711,000Source |
| GoodwillUSD | — | — | 10,502,000Source | 10,502,000Source | 10,502,000Source | 10,502,000Source | 10,502,000Source | 10,502,000Source | 10,502,000Source | 10,502,000Source | 10,502,000Source | 14,409,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | — | 0Source | 3,907,000Source | — |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | — | — | — | — | — | — | — | — | — | -41,658,000Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Income Tax Expense (Benefit)USD | — | — | 11,000Source | -14,000Source | 18,000Source | 16,000Source | 12,000Source | 8,000Source | 165,000Source | 114,000Source | 14,000Source | 28,000Source |
| Liability for Unpaid Claims and Claims Adjustment Expense, Incurred ClaimsUSD | — | — | — | — | — | — | — | — | — | — | — | 500,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -30,625,000Source | 23,037,000Source | -36,358,000Source | -20,765,000Source | -19,630,000Source | -13,149,000Source | -78,259,000Source | -35,129,000Source | -31,544,000Source | -41,658,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -30,625,000Source | 5,462,000Source | -36,358,000Source | -20,765,000Source | -19,630,000Source | -13,149,000Source | — | -35,129,000Source | — | — |
| Nonoperating Income (Expense)USD | — | — | -11,416,000Source | 35,884,000Source | -4,823,000Source | -1,433,000Source | 1,283,000Source | 1,528,000Source | -5,169,000Source | 33,497,000Source | -4,179,000Source | -4,190,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -3,000Source | -5,000Source | — | -5,000Source | — | — | — | -5,000Source | -42,000Source | -20,000Source |
| Payments for Repurchase of WarrantsUSD | — | — | — | — | — | — | — | — | 0Source | 1,734,000Source | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 14,762,000Source | 0Source | 46,200,000Source | 0Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 2,178,000Source | 0Source | 774,000Source | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 0Source | 249,000Source | — | — | — | — | 59,000Source | 441,000Source | 1,924,000Source | 18,051,000Source |
| Cost of RevenueUSD | — | — | — | -714,000Source | — | 0Source | — | — | — | — | 1,284,000Source | 3,434,000Source |
| Gross Profit (Calculated) · Derived | — | — | — | — | — | — | — | — | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 10,300,000Source | — |
| Operating Income (Loss)USD | — | — | -19,198,000Source | -12,861,000Source | -31,517,000Source | -19,316,000Source | -20,901,000Source | -14,669,000Source | -72,925,000Source | -68,512,000Source | -27,351,000Source | -37,440,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -3,000Source | -5,000Source | — | -5,000Source | — | — | — | -5,000Source | -42,000Source | -20,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -30,614,000Source | 23,023,000Source | -36,340,000Source | -20,749,000Source | -19,618,000Source | -13,141,000Source | -78,094,000Source | -35,015,000Source | -31,530,000Source | — |
| Income Tax Expense (Benefit)USD | — | — | 11,000Source | -14,000Source | 18,000Source | 16,000Source | 12,000Source | 8,000Source | 165,000Source | 114,000Source | 14,000Source | 28,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -30,625,000Source | 23,037,000Source | -36,358,000Source | -20,765,000Source | -19,630,000Source | -13,149,000Source | -78,259,000Source | -35,129,000Source | -31,544,000Source | -41,658,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -2.19Source | 0.98Source | -0.83Source | -1.92Source | -0.98Source | -1.25Source | -5.84Source | -7.94Source | -114Source | -4.43Source |
| Earnings Per Share, DilutedUSD per share | — | — | -2.19Source | -2.83Source | -0.83Source | -1.92Source | -0.98Source | -1.25Source | -5.84Source | -20.91Source | -114Source | -4.43Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 14,000,451Source | 5,546,257Source | 43,602,044Source | 10,829,760Source | 20,106,925Source | 10,514,901Source | 13,404,830Source | 4,426,149Source | 277,727Source | 9,408,477Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 14,000,451Source | 10,784,037Source | 43,602,044Source | 10,829,760Source | 20,106,925Source | 10,514,901Source | 13,404,830Source | 7,496,389Source | 277,727Source | 9,408,477Source |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 38,000Source |
| Costs and ExpensesUSD | — | — | 19,198,000Source | 13,110,000Source | 31,517,000Source | 19,316,000Source | 20,901,000Source | 14,669,000Source | 72,984,000Source | 68,953,000Source | 29,275,000Source | 55,491,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| General and Administrative ExpenseUSD | — | — | 5,577,000Source | 4,286,000Source | 8,099,000Source | 5,242,000Source | 6,854,000Source | 5,546,000Source | 22,900,000Source | 17,241,000Source | — | 20,711,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | — | 0Source | 3,907,000Source | — |
| Income (Loss) Attributable to Parent, before TaxUSD | — | — | — | — | — | — | — | — | — | — | — | -41,630,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | — | — | — | — | — | — | — | — | — | -41,658,000Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | 1,117,000Source | 964,000Source | 2,761,000Source | 1,097,000Source | 803,000Source | 1,148,000Source | 4,351,000Source | 3,317,000Source | -3,417,000Source | -4,170,000Source |
| Liability for Unpaid Claims and Claims Adjustment Expense, Incurred ClaimsUSD | — | — | — | — | — | — | — | — | — | — | — | 500,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -30,625,000Source | 5,462,000Source | -36,358,000Source | -20,765,000Source | -19,630,000Source | -13,149,000Source | — | -35,129,000Source | — | — |
| Nonoperating Income (Expense)USD | — | — | -11,416,000Source | 35,884,000Source | -4,823,000Source | -1,433,000Source | 1,283,000Source | 1,528,000Source | -5,169,000Source | 33,497,000Source | -4,179,000Source | -4,190,000Source |
| Undistributed Earnings (Loss) Allocated to Participating Securities, Basic | — | — | — | —Source | — | — | — | — | — | — | — | — |
Offerings
Registration 333-299835
Registration 333-297528
Registration 333-292614
Filing attachments
tm2628581d2_ex4-6.htm · S-3ASR · 2026-11-05
Exhibit 4.6 AVALO THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [· ], 202[· ] Senior Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTI…
Read attachment ↗tm2628581d2_ex4-7.htm · S-3ASR · 2026-11-05
Exhibit 4.7 AVALO THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [• ], 202[• ] Subordinated Debt Securities TABLE OF CONTENTS 1 ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1…
Read attachment ↗p12168489_ex99-1.htm · SCHEDULE 13G · 2026-05-26
EXHIBIT 99.1 JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the …
Read attachment ↗tenxex99_1.htm · SCHEDULE 13G/A · 2026-05-15
EXHIBIT 99.1 AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D, Schedule 13G or forms 3, 4 or 5 (and any amendments or supplements thereto) required under section 13(d) or 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigned …
Read attachment ↗tm2613717d1_ex4-1.htm · 8-K · 2026-05-07
EX-4.1 3 tm2613717d1_ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 AVALO THERAPEUTICS, INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. [ ] Original Issue Date: [__], 2026 Avalo Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [___], or its permitted registered assigns (the “Holder”), is entitled, sub…
Read attachment ↗tenxex99_1.htm · SCHEDULE 13G · 2026-04-01
EXHIBIT 99.1 AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D, Schedule 13G or forms 3, 4 or 5 (and any amendments or supplements thereto) required under section 13(d) or 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigned …
Read attachment ↗